These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29726082)

  • 1. Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.
    Overbeek JA; Heintjes EM; Huisman EL; Tikkanen CK; van Diermen AW; Penning-van Beest FJA; Herings RMC
    Diabetes Obes Metab; 2018 Sep; 20(9):2093-2102. PubMed ID: 29726082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Price H; Blüher M; Prager R; Phan TM; Thorsted BL; Schultes B;
    Diabetes Obes Metab; 2018 Apr; 20(4):954-962. PubMed ID: 29205856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
    Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
    Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.
    Thayer S; Wei W; Buysman E; Brekke L; Crown W; Grabner M; Raparla S; Quimbo R; Cziraky MJ; Hu W; Cuddihy R
    Adv Ther; 2013 Dec; 30(12):1128-40. PubMed ID: 24293131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.
    Szépkúti S; Bandur S; Kovács G; Ferenci T; Svébis MM; Turbucz P; Tabák ÁG
    BMC Endocr Disord; 2022 Sep; 22(1):229. PubMed ID: 36104712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?
    Watson L; Wilson BP; Alsop J; Kumar S
    Diabetes Obes Metab; 2011 Sep; 13(9):823-31. PubMed ID: 21481128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
    Simioni N; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Lapolla A; Bette C; Rossi MC;
    Acta Diabetol; 2018 Jun; 55(6):557-568. PubMed ID: 29527621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
    Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
    Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
    Abreu M; Tumyan A; Elhassan A; Peicher K; Papacostea O; Dimachkie P; Siddiqui MS; Pop LM; Gunasekaran U; Meneghini LF; Adams-Huet B; Li X; Lingvay I
    Diabetes Obes Metab; 2019 Sep; 21(9):2133-2141. PubMed ID: 31144435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
    Bizino MB; Jazet IM; van Eyk HJ; Rensen PCN; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Paiman EHM; Smit JW; Lamb HJ
    Acta Diabetol; 2021 Apr; 58(4):485-493. PubMed ID: 33399989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.